Nemaura Medical

Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOUGHBOROUGH, England--( BUSINESS WIRE )--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announced receipt of a first purchase order for 5,000 proBEAT™ subscriptions from HealthFleet Inc. (“HealthFleet”), a leading telehealth provider focusing on care, coaching, and health recommendations. The purchase order consists of 75,000 proBEAT glucose sensors over an initial five month period and is valued at $500,000 in revenue. HealthFleet has an option to increase volumes based on customer response.

Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

LOUGHBOROUGH, England--( BUSINESS WIRE )--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, announces initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the United Kingdom.

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that CEO Dr. Faz Chowdhury will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on January 18 -19, 2023.

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.

Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022

LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that it has commenced patient studies of its proprietary metabolic health program, Miboko, with the National Health Service (NHS) in the United Kingdom.

Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 0% and 75.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Nemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue Estimates

Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the Bernstein 2nd Annual CGM Disruptors Conference which is being held virtually on November 18, 2022.

Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference

ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 5, at 7 p.m. Eastern Time (ET).

Nemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

LOUGHBOROUGH, ENGLAND, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced it has received a provisional purchase order from TPMENA, its MENA (Middle East/North Africa) licensee for the Company's sugarBEAT® system.

Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA

CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it has entered into a preliminary agreement with EVERSANA ® , a pioneer of next-generation commercial services to the global life sciences industry.

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura's Diabetes Management Program in the U.S.

Loughborough, England, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference, which is being held on September 12 – 14, 2022.

Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of -6.25% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Nemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates

Loughborough, England, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases its financial results for the quarter ending June 30, 2022 and provides a business update.

Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update

Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured $5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements. As part of the current financing, existing debt repayments have been deferred for nine months.

Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding

Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that its UK licensee, MySugarWatch, has continued its large scale awareness campaign for the Company's sugarBEAT non-invasive continuous glucose monitor by commencing a direct-to-consumer campaign in one of the UK's largest daily newspaper, Daily Mail.

MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical's sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail

Loughborough, England, April 25, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present virtually at the Planet MicroCap Showcase 2022. The conference is being held on May 3 – 5, 2022 at The Bally's Hotel & Casino in Las Vegas, NV.

Nemaura Medical to Present at the Planet MicroCap Showcase 2022

Loughborough, England, March 24, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held on March 28-30, 2022.

Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference

The Continuous Glucose Monitoring Market is expanding to consumer-centered CGM wellness devices, targeting Type-2 diabetics, prediabetics, and healthy consumers.

Nemaura Medical: Opportunity In The Consumer-Centered Continuous Glucose Monitoring Market

Loughborough, England, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces it received the top award as Innovator of the Year at the LeicestershireLive Innovation Awards 2022 held on February 24, 2022. Additionally, the Company was also awarded top honors for Innovation in MedTech and Life Sciences.

Nemaura Medical Wins Innovation Awards

Loughborough, England, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the third quarter of fiscal 2022 (for the three months ended December 31, 2021).

Nemaura Medical Announces Fiscal Third Quarter 2022 Financial Results and Provides Business Update

Launch into commercial markets offers opportunit ies for faster and wider adoption of Mi b o k o program

Nemaura Medical Launches Metabolic Health Program for Employers and Insurers

Loughborough, England, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

Nemaura Medical to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference

Sales in UK expected to be followed by launches across major EU territories in 2022

Nemaura Medical Completes Initial Shipment of CGM Devices to UK Licensee

Loughborough, England, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the second quarter of fiscal 2022 (for the three months ended September 30, 2021).

Nemaura Medical Announces Fiscal Second Quarter 2022 Financial Results and Provides Business Update

Loughborough, England, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will be presenting virtually at the Diabetes Technology Society Annual Meeting on November 4, 2021 at 2:00 PM ET.

News for Nemaura Medical Stock (NMRD)